TY  -  
T1  - Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe 
SN  -  /  
UR  - http://hdl.handle.net/10138/174092 
T3  -  
A1  - Hofstra, L. Marije; Sauvageot, Nicolas; Albert, Jan; Alexiev, Ivailo; Garcia, Federico; Struck, Daniel; Van de Vijver, David A. M. C.; Asjo, Birgitta; Beshkov, Danail; Coughlan, Suzie; Descamps, Diane; Griskevicius, Algirdas; Hamouda, Osamah; Horban, Andrzej; Van Kasteren, Marjo; Kolupajeva, Tatjana; Kostrikis, Leondios G.; Liitsola, Kirsi; Linka, Marek; Mor, Orna; Nielsen, Claus; Otelea, Dan; Paraskevis, Dimitrios; Paredes, Roger; Poljak, Mario; Puchhammer-Stoeckl, Elisabeth; Sonnerborg, Anders; Stanekova, Danica; Stanojevic, Maja; Van Laethem, Kristel; Zazzi, Maurizio; Lepej, Snjezana Zidovec; Boucher, Charles A. B.; Schmit, Jean-Claude; Wensing, Annemarie M. J.; SPREAD Program; Ristola, M. 
A2  -  
PB  -  
Y1  - 2016 
LA  - eng 
AB  - Background. Numerous studies have shown that baseline drug resistance patterns may influence the outcome of antiretroviral therapy. Therefore, guidelines recommend drug resistance testing to guide the choice of initial regimen. In addition to optimizing individual patient management, these baseline resistance data enable transmitted drug resistance (TDR) to be surveyed for public health purposes. The SPREAD program systematically collects data to gain insight into TDR occurring in Europe since 2... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - HIV-1; drug resistance; transmission; antiretroviral therapy; Europe; REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL TREATMENT; INFECTION; INDIVIDUALS; RILPIVIRINE; MUTATIONS; PREVALENCE; ETRAVIRINE; INTEGRASE; EFAVIRENZ; 3121 General medicine, internal medicine and other clinical medicine 
N1  -   
PP  -  
ER  -